3,3-difluorocyclobutanamine hydrochloride

3,3-difluorocyclobutylamine hydrochloride is a key intermediate for the 2018 FDA new batch of drug Evonib. Tibsovo is a highly effective oral targeted inhibitor of IDH1 gene mutation cancer, which is the first in its class and has selectivity. It has been approved by the FDA for the treatment of adult patients with specific "IDH1" gene mutations and relapsed or refractory acute myeloid leukemia (AML).